Patient-derived xenograft models of prostate tumors

P.J. Russell, E. D. Williams, R. Taylor, M.G. Lawrence, G. Risbridger

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

Abstract

In contrast to many other solid tumor types, the potential of using patient-derived xenografts (PDXs) from prostate cancer for preclinical research has yet to be fully realized. Prostate cancer PDXs are notoriously difficult to establish and this section provides a state-of-the-art summary including the effect of implantation site on revealing metastatic potential and the role of the microenvironment in supporting take rate and model fidelity. Tissue recombination is described as a technique that can improve the take rate of prostate xenografts that span the stages of prostate cancer progression. Comparisons of the pathology and molecular profiles of short- and long-term transplantable xenografts are made to describe their potential for studies of tumor biology and for preclinical applications involving patient-directed/targeted therapies.

Original languageEnglish
Title of host publicationPatient Derived Tumor Xenograft Models: Promise, Potential and Practice
EditorsRajesh Uthamanthil, Peggy Tinkey, Elisa de Stanchina
PublisherElsevier
Pages217-228
Number of pages12
ISBN (Electronic)9780128040614
ISBN (Print)9780128040102
DOIs
Publication statusPublished - 2017

Keywords

  • Humanized
  • Implantation sites: subrenal capsule, subcutaneous, intraprostatic
  • Patient-derived xenografts (PDX)
  • Prostate cancer
  • Stromal precursors
  • Tissue recombination
  • Urogenital mesenchyme

Cite this

Russell, P. J., Williams, E. D., Taylor, R., Lawrence, M. G., & Risbridger, G. (2017). Patient-derived xenograft models of prostate tumors. In R. Uthamanthil, P. Tinkey, & E. de Stanchina (Eds.), Patient Derived Tumor Xenograft Models: Promise, Potential and Practice (pp. 217-228). Elsevier. https://doi.org/10.1016/B978-0-12-804010-2.00016-3
Russell, P.J. ; Williams, E. D. ; Taylor, R. ; Lawrence, M.G. ; Risbridger, G. / Patient-derived xenograft models of prostate tumors. Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. editor / Rajesh Uthamanthil ; Peggy Tinkey ; Elisa de Stanchina. Elsevier, 2017. pp. 217-228
@inbook{d89017276e934bba8bed63a326c92e89,
title = "Patient-derived xenograft models of prostate tumors",
abstract = "In contrast to many other solid tumor types, the potential of using patient-derived xenografts (PDXs) from prostate cancer for preclinical research has yet to be fully realized. Prostate cancer PDXs are notoriously difficult to establish and this section provides a state-of-the-art summary including the effect of implantation site on revealing metastatic potential and the role of the microenvironment in supporting take rate and model fidelity. Tissue recombination is described as a technique that can improve the take rate of prostate xenografts that span the stages of prostate cancer progression. Comparisons of the pathology and molecular profiles of short- and long-term transplantable xenografts are made to describe their potential for studies of tumor biology and for preclinical applications involving patient-directed/targeted therapies.",
keywords = "Humanized, Implantation sites: subrenal capsule, subcutaneous, intraprostatic, Patient-derived xenografts (PDX), Prostate cancer, Stromal precursors, Tissue recombination, Urogenital mesenchyme",
author = "P.J. Russell and Williams, {E. D.} and R. Taylor and M.G. Lawrence and G. Risbridger",
note = "Section III: Chapter 2",
year = "2017",
doi = "10.1016/B978-0-12-804010-2.00016-3",
language = "English",
isbn = "9780128040102",
pages = "217--228",
editor = "Rajesh Uthamanthil and Tinkey, {Peggy } and {de Stanchina}, {Elisa }",
booktitle = "Patient Derived Tumor Xenograft Models: Promise, Potential and Practice",
publisher = "Elsevier",
address = "Netherlands",

}

Russell, PJ, Williams, ED, Taylor, R, Lawrence, MG & Risbridger, G 2017, Patient-derived xenograft models of prostate tumors. in R Uthamanthil, P Tinkey & E de Stanchina (eds), Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Elsevier, pp. 217-228. https://doi.org/10.1016/B978-0-12-804010-2.00016-3

Patient-derived xenograft models of prostate tumors. / Russell, P.J.; Williams, E. D.; Taylor, R.; Lawrence, M.G.; Risbridger, G.

Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. ed. / Rajesh Uthamanthil; Peggy Tinkey; Elisa de Stanchina. Elsevier, 2017. p. 217-228.

Research output: Chapter in Book/Report/Conference proceedingChapter (Book)Researchpeer-review

TY - CHAP

T1 - Patient-derived xenograft models of prostate tumors

AU - Russell, P.J.

AU - Williams, E. D.

AU - Taylor, R.

AU - Lawrence, M.G.

AU - Risbridger, G.

N1 - Section III: Chapter 2

PY - 2017

Y1 - 2017

N2 - In contrast to many other solid tumor types, the potential of using patient-derived xenografts (PDXs) from prostate cancer for preclinical research has yet to be fully realized. Prostate cancer PDXs are notoriously difficult to establish and this section provides a state-of-the-art summary including the effect of implantation site on revealing metastatic potential and the role of the microenvironment in supporting take rate and model fidelity. Tissue recombination is described as a technique that can improve the take rate of prostate xenografts that span the stages of prostate cancer progression. Comparisons of the pathology and molecular profiles of short- and long-term transplantable xenografts are made to describe their potential for studies of tumor biology and for preclinical applications involving patient-directed/targeted therapies.

AB - In contrast to many other solid tumor types, the potential of using patient-derived xenografts (PDXs) from prostate cancer for preclinical research has yet to be fully realized. Prostate cancer PDXs are notoriously difficult to establish and this section provides a state-of-the-art summary including the effect of implantation site on revealing metastatic potential and the role of the microenvironment in supporting take rate and model fidelity. Tissue recombination is described as a technique that can improve the take rate of prostate xenografts that span the stages of prostate cancer progression. Comparisons of the pathology and molecular profiles of short- and long-term transplantable xenografts are made to describe their potential for studies of tumor biology and for preclinical applications involving patient-directed/targeted therapies.

KW - Humanized

KW - Implantation sites: subrenal capsule, subcutaneous, intraprostatic

KW - Patient-derived xenografts (PDX)

KW - Prostate cancer

KW - Stromal precursors

KW - Tissue recombination

KW - Urogenital mesenchyme

UR - http://www.scopus.com/inward/record.url?scp=85020659871&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-804010-2.00016-3

DO - 10.1016/B978-0-12-804010-2.00016-3

M3 - Chapter (Book)

SN - 9780128040102

SP - 217

EP - 228

BT - Patient Derived Tumor Xenograft Models: Promise, Potential and Practice

A2 - Uthamanthil, Rajesh

A2 - Tinkey, Peggy

A2 - de Stanchina, Elisa

PB - Elsevier

ER -

Russell PJ, Williams ED, Taylor R, Lawrence MG, Risbridger G. Patient-derived xenograft models of prostate tumors. In Uthamanthil R, Tinkey P, de Stanchina E, editors, Patient Derived Tumor Xenograft Models: Promise, Potential and Practice. Elsevier. 2017. p. 217-228 https://doi.org/10.1016/B978-0-12-804010-2.00016-3